2191 - 2200 of 8093 Results
Title
Year
- Combining Multimodal Biomarkers to Guide Deep Brain Stimulation Programming in Parkinson Disease2022OPENTitle: Combining Multimodal Biomarkers to Guide Deep Brain Stimulation Programming in Parkinson DiseaseJournal Name: Neuromodulation: Technology at the Neural InterfacePublisher: Elsevier BVVol: 26Issue #: 2Start Page: 320End Page: 332Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.neurom.2022.01.017Best OA location URL: http://www.neuromodulationjournal.org/article/S1094715922000381/pdfCitation Count: 35
- Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes2022OPENTitle: Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypesJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 167Issue #:Start Page: 105668End Page: 105668Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nbd.2022.105668Best OA location URL: https://doi.org/10.1016/j.nbd.2022.105668Citation Count: 20
-
OPENTitle: Defining Utility Values for Chorea Health States in Patients with Huntington’s DiseaseJournal Name: Advances in TherapyPublisher: Springer Science and Business Media LLCVol: 39Issue #: 4Start Page: 1784End Page: 1793Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s12325-022-02046-zBest OA location URL: https://link.springer.com/content/pdf/10.1007/s12325-022-02046-z.pdfCitation Count: 3
- Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads2022OPENTitle: Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beadsJournal Name: eLifePublisher: eLife Sciences Publications, LtdVol: 11Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.7554/elife.73971Best OA location URL: https://doi.org/10.7554/elife.73971Citation Count: 53
- Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study2022OPENTitle: Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.773999Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.773999/pdfCitation Count: 7
- Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease2022